Eribulin mesylate in patients with refractory cancers: a Phase I study

Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This Phase I study (clinicaltrials.gov identifier: NCT00326950) was the first to investigate eribulin mesylate in Japan...

Descripción completa

Detalles Bibliográficos
Autores principales: Mukohara, Toru, Nagai, Shunji, Mukai, Hirofumi, Namiki, Masayuki, Minami, Hironobu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2011
Materias:
Phase I Studies
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432792/
https://www.ncbi.nlm.nih.gov/pubmed/21887501
http://dx.doi.org/10.1007/s10637-011-9741-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3432792/
https://www.ncbi.nlm.nih.gov/pubmed/21887501
http://dx.doi.org/10.1007/s10637-011-9741-2

Ejemplares similares